How to Invest in United Therapeutics?
United Therapeutics Investing Guide | UTHR |
- Research United Therapeutics' stock before investing in United Therapeutics. It's a good idea to research the company and its stock by analyzing its financial statements, reading news articles, and studying its historical performance, including its growth strategy, change in net worth, competition, and potential risks.
- Choose a brokerage firm to buy shares of United Therapeutics. We recommend well-established brokerages such as Charles Schwab, Fidelity, TD Ameritrade, and Robinhood, but in many ways, it will depend on your individual needs, preferences, and investment goals.
- Open an account at one of the brokerages you have selected. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account. You will need to deposit funds into your brokerage account to purchase United Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order. Once you have located United Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock.
It's important to note that investing in stocks such as United Therapeutics carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions regarding United Stock. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to invest safely in United Therapeutics.
Research United Therapeutics Stock
Researching United Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E).
About 98.0% of the company outstanding shares are owned by institutional investors. The book value of United Therapeutics was at this time reported as 136.74. The company has Price/Earnings To Growth (PEG) ratio of 1.56. United Therapeutics recorded earning per share (EPS) of 22.76. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 23rd of September 2009. United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. United Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 965 people. For more information please call the company at 301 608 9292 or visit https://www.unither.com. Other things to consider when investing in United
Another important aspect of United Therapeutics' research is to evaluate the company's potential for future growth. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding United Therapeutics' research are outlined below:
| United Therapeutics is unlikely to experience financial distress in the next 2 years | |
| Over 98.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Should You Invest in the Invesco Biotechnology Genome ETF |
United Therapeutics Quarterly Cost Of Revenue |
|
Check United Therapeutics' earnings reports
United Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in United Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to United Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Use historical earnings surprises to time your United Therapeutics position
Earnings surprises can significantly impact United Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises United Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2003-11-06 | 2003-09-30 | -0.04 | -0.03 | 0.01 | 25 | ||
2005-05-03 | 2005-03-31 | 0.14 | 0.16 | 0.02 | 14 | ||
2003-05-06 | 2003-03-31 | -0.09 | -0.07 | 0.02 | 22 | ||
2003-02-25 | 2002-12-31 | -0.08 | -0.06 | 0.02 | 25 | ||
2002-11-08 | 2002-09-30 | -0.16 | -0.14 | 0.02 | 12 | ||
2010-04-29 | 2010-03-31 | 0.29 | 0.32 | 0.03 | 10 | ||
2008-05-01 | 2008-03-31 | 0.27 | 0.24 | -0.03 | 11 | ||
2004-05-06 | 2004-03-31 | -0.01 | -0.04 | -0.03 | 300 |
Know United Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as United Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading United Therapeutics backward and forwards among themselves. United Therapeutics' institutional investor refers to the entity that pools money to purchase United Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Aqr Capital Management Llc | 2024-06-30 | 719.5 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 621 K | Fuller & Thaler Asset Management Inc | 2024-09-30 | 568.4 K | Pacer Advisors, Inc. | 2024-06-30 | 561.8 K | Alliancebernstein L.p. | 2024-06-30 | 539.6 K | Amundi | 2024-06-30 | 473 K | Arrowstreet Capital Limited Partnership | 2024-06-30 | 438.7 K | Bank Of New York Mellon Corp | 2024-06-30 | 434.8 K | Nuveen Asset Management, Llc | 2024-06-30 | 434.5 K | Blackrock Inc | 2024-06-30 | 5.5 M | Vanguard Group Inc | 2024-09-30 | 4.4 M |
Follow United Therapeutics' market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 16.27 B.Market Cap |
|
Evaluate United Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.14 | 0.15 | |
| Return On Capital Employed | 0.19 | 0.20 | |
| Return On Assets | 0.14 | 0.14 | |
| Return On Equity | 0.16 | 0.17 |
Determining United Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to assess its ability to generate profits. Also, when deciding whether to invest in United Therapeutics, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures United Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of United Therapeutics' profitability and make more informed investment decisions.
Evaluate United Therapeutics' management efficiency
United Therapeutics has return on total asset (ROA) of 0.1189 % which means that it generated a profit of $0.1189 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1881 %, meaning that it created $0.1881 on every $100 dollars invested by stockholders. United Therapeutics' management efficiency ratios could be used to measure how well United Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/22/2024, Return On Tangible Assets is likely to grow to 0.15. Also, Return On Capital Employed is likely to grow to 0.20. At this time, United Therapeutics' Return On Tangible Assets are relatively stable compared to the past year. As of 11/22/2024, Debt To Assets is likely to grow to 0.10, while Other Assets are likely to drop slightly above 284.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 127.88 | 134.27 | |
| Tangible Book Value Per Share | 125.44 | 131.71 | |
| Enterprise Value Over EBITDA | 7.05 | 10.85 | |
| Price Book Value Ratio | 1.72 | 1.63 | |
| Enterprise Value Multiple | 7.05 | 10.85 | |
| Price Fair Value | 1.72 | 1.63 | |
| Enterprise Value | 11.2 B | 11.8 B |
Examining the leadership quality of United Therapeutics offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Beta 0.561 |
Basic technical analysis of United Stock
As of the 22nd of November, United Therapeutics has the Semi Deviation of 1.89, coefficient of variation of 1925.95, and Risk Adjusted Performance of 0.0447. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of United Therapeutics, as well as the relationship between them. Please validate United Therapeutics coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if United Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 367.36 per share. Given that United Therapeutics has jensen alpha of (0.01), we advise you to double-check United Therapeutics's current market performance to make sure the company can sustain itself at a future point.Check United Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific United Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on United Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases United Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Evaluate United Therapeutics' Outstanding Corporate Bonds
United Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. United Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most United bonds can be classified according to their maturity, which is the date when United Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| UNITED TECHNOLOGIES P Corp BondUS913017CR85 | View | |
| UNITED TECHNOLOGIES P Corp BondUS913017CP20 | View | |
| UNITED TECHNOLOGIES P Corp BondUS913017CW70 | View | |
| UNITED TECHNOLOGIES P Corp BondUS913017CY37 | View | |
| UNITED TECHNOLOGIES P Corp BondUS913017CX53 | View | |
| Dana 575 percent Corp BondUS235822AB96 | View | |
| UNITED TECHNOLOGIES P Corp BondUS913017DD80 | View | |
| UNITED TECHNOLOGIES P Corp BondUS913017BP39 | View |
United Therapeutics' technical indicators
Using predictive indicators to make investment decisions involves analyzing United Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0447 | |||
| Market Risk Adjusted Performance | 0.0843 | |||
| Mean Deviation | 1.21 | |||
| Semi Deviation | 1.89 | |||
| Downside Deviation | 2.02 | |||
| Coefficient Of Variation | 1925.95 | |||
| Standard Deviation | 1.71 | |||
| Variance | 2.94 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.12) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.0743 | |||
| Maximum Drawdown | 9.81 | |||
| Value At Risk | (3.07) | |||
| Potential Upside | 2.89 | |||
| Downside Variance | 4.08 | |||
| Semi Variance | 3.57 | |||
| Expected Short fall | (1.14) | |||
| Skewness | (0.83) | |||
| Kurtosis | 2.4 |
| Risk Adjusted Performance | 0.0447 | |||
| Market Risk Adjusted Performance | 0.0843 | |||
| Mean Deviation | 1.21 | |||
| Semi Deviation | 1.89 | |||
| Downside Deviation | 2.02 | |||
| Coefficient Of Variation | 1925.95 | |||
| Standard Deviation | 1.71 | |||
| Variance | 2.94 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.12) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.0743 | |||
| Maximum Drawdown | 9.81 | |||
| Value At Risk | (3.07) | |||
| Potential Upside | 2.89 | |||
| Downside Variance | 4.08 | |||
| Semi Variance | 3.57 | |||
| Expected Short fall | (1.14) | |||
| Skewness | (0.83) | |||
| Kurtosis | 2.4 |
Consider United Therapeutics' intraday indicators
United Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of United Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
United Therapeutics Corporate Filings
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 30th of October 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
13A | 16th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Choose a brokerage platform to buy United Therapeutics' shares
In investing, finding the right broker is a crucial step for anyone looking to embark on a journey into the stock market. It all begins with a thorough comparison of costs and fees, as low-cost or commission-free brokers can significantly impact an investor's returns. However, the cheapest option is not always the best choice. The adventure continues with exploring various trading platforms, seeking one that is user-friendly, reliable, and functional. The ideal platform will provide the necessary research, analysis, and investment monitoring tools. As the quest goes on, it's essential to consider the different account types brokers offer, such as individual, joint, and retirement accounts. In addition, for those interested in trading on margin, brokers offering margin accounts should also be considered. The journey leads to the discovery of brokers that provide a wide range of investment options, including stocks, bonds, ETFs, and mutual funds. This diversity allows investors to build well-rounded portfolios that suit their needs and goals. Customer service is another crucial factor in this decision-making process. The perfect broker would have a responsive, knowledgeable, and available customer support team ready to assist with various issues or investment decisions. Aspiring investors should seek brokers with quality research, market analysis, and educational resources. These tools are essential for making informed decisions and improving investment knowledge. It's also vital to ensure that the broker is regulated by an appropriate regulatory body and has robust security measures to protect personal and financial information. Additionally, account minimums and funding options should be taken into consideration. A broker with flexible account minimums and various funding options, such as wire transfers, ACH transfers, or check deposits, will cater to different investor needs. A seamless mobile and web experience is a must in today's fast-paced world. The ideal broker will allow investors to manage their investments easily on the go. Finally, it is essential to consider various brokers' reviews and conduct reputation analysis. By reading online assessments and seeking recommendations, valuable insights into each broker's reputation can be gathered. After a thorough investigation, you can find a broker that checks all the boxes and aligns with their preferences and requirements regarding taking a position in United Therapeutics.
Open brokerage account to buy United Stock
Once you've selected a broker, visit their website or a local branch to initiate the account-opening process. Most brokers offer online account opening, which is typically faster and more convenient. When you begin the process, you'll need to select the type of account you want to open. This may include individual, joint, or retirement accounts. Some brokers may also offer margin accounts, which allow you to trade on margin. Next, you'll need to complete the application form. Whether you're filling out an online or paper application, you'll need to provide personal information, such as your name, address, Social Security Number or other tax identification number, date of birth, and employment information. You may also be asked about your investment experience, financial situation, and goals. After completing the application form, review it carefully for accuracy and submit it to the broker. Some brokers may require you to provide additional documentation, such as a copy of your driver's license or passport, for identity verification. Once your application is submitted, the broker will review it and may run a background check or verify your credit history. You'll receive an email or notification with your new brokerage account details if your application is approved.
Fund your account to invest in United Stock
Once your account is open, you can fund it by linking your bank account to your brokerage account. To do this, log in to your brokerage account and look for an option to add or link a bank account. You will need to provide your bank account number and the routing number for your bank. This information can be found on your checks or by contacting your bank. After linking your bank account, you can initiate a transfer of funds from your bank account to your brokerage account. This process may vary depending on the brokerage, but generally, you will need to navigate to the funding or deposit section of the brokerage website or app. From there, you can choose the linked bank account and enter the amount you wish to transfer. Keep in mind that there may be limits on the amount you can transfer in a single transaction, and the transfer may take several business days to complete. Some brokerages also offer other funding options, such as wire transfers, mailing a check, or transferring assets from another brokerage. If you prefer to use one of these methods, check with your brokerage firm for specific instructions. Once the funds are in your brokerage account, you can use them to purchase investments such as stocks, bonds, mutual funds, or other financial instruments.
Place your United Stock order
Placing an United Therapeutics purchase order involves providing instructions to your selected brokerage firm to aquare shares of United Therapeutics on your behalf. First, your will need to access your brokerage account through their website or mobile app using your login credentials. Make sure you have sufficient funds in your account to cover the cost of the stock purchase, including any applicable fees or commissions. Once you are logged in, locate the trading platform or order entry section within the brokerage interface. It may be labeled as "Trade," "Order Entry," or something similar. Next, you will need to provide the necessary information to place your stock order. This typically includes: .
After entering the necessary information, review your order carefully to ensure it reflects your intentions accurately. When you are ready, submit your order by clicking the "Submit," "Place Order," or equivalent button. Your brokerage firm will then execute your order according to your instructions, subject to market conditions and the availability of shares. Keep in mind that market orders may be executed immediately, while limit orders, stop orders, and stop-limit orders will only be executed if the specified conditions are met. Finally, monitor your order status and confirm its execution. You can usually find this information in the "Order History" or "Order Status" section of your brokerage account.
| Ticker | Enter the ticker symbol, which is the unique series of letters representing the stock, e.g., UTHR for United Therapeutics | |
| Type | Choose the type of order you want to place. The most common order types are market orders, limit orders, stop orders, and stop-limit orders. Each order type has its own advantages and drawbacks, so be sure to research and understand them before placing your order. | |
| Quantity | Specify the number of shares you want to buy or sell | |
| Duration | Indicate the duration for which your order will be active. You can choose from options like "Day" (valid only for the current trading day) or "Good 'til Canceled" (valid until you manually cancel the order) |
Monitor your United Stock position
Monitoring your stock positions with your brokerage involves regularly checking the status and performance of your investments. Here's how you can monitor your stock positions using your brokerage account: First, access your account by signing in to your brokerage firm's website or mobile app using your login credentials. Once you're logged in, look for the section that displays your account information and portfolio holdings. This section may be labeled as "Portfolio," "Positions," "Holdings," or something similar. In this section, you'll generally find a list of the stocks and other investments that you own, along with relevant details such as the number of shares, the current market value, and the percentage change in value since the last trading day's close. You might also see the total cost of your investment, your current profit or loss, and the percentage gain or loss. Many brokerages also provide tools and features that allow you to analyze and track your stock positions more effectively. These may include:
As you continue to monitor your United Stock position, remember that in order to be an effective trader, it is critical to understand your entire portfolio's sensitivity to market volatility and how your single United Therapeutics position affects your overall exposure to market risk. One of the techniques to manage your overall risk is pair trading, a market-neutral trading strategy enabling traders to profit from virtually any market condition, whether it is experiencing an uptrend or downtrend movement.
| Performance Charts | These charts visually represent the historical price movement of your stocks over different time frames. You can use them to assess the trends and volatility of your investments. | |
| Stock Alerts | You can set up custom alerts to receive notifications when a stock reaches a certain price, percentage change, or other criteria. This can help you stay informed about significant market movements affecting your investments. | |
| Watchlists | Create watchlists to track the performance of stocks you are interested in but have not yet purchased. This can help you identify potential opportunities or risks. | |
| Research Tools | Brokerages often provide access to research tools, such as stock screeners, analyst reports, and financial statements, to help you make more informed investment decisions. |
Moving together with United Stock
Moving against United Stock
| 0.74 | PALI | Palisade Bio | PairCorr |
| 0.66 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.64 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.59 | INZY | Inozyme Pharma | PairCorr |
| 0.54 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.48 | KTTA | Pasithea Therapeutics | PairCorr |
| 0.48 | KURA | Kura Oncology | PairCorr |
| 0.47 | BDRX | Biodexa Pharmaceticals Upward Rally | PairCorr |
| 0.44 | TERN | Terns Pharmaceuticals | PairCorr |
| 0.39 | DYN | Dyne Therapeutics | PairCorr |
| 0.39 | XFOR | X4 Pharmaceuticals | PairCorr |
| 0.35 | VRAX | Virax Biolabs Group | PairCorr |
| 0.31 | GOSS | Gossamer Bio | PairCorr |
Follow United Stock across various news and media outlets
Far too much social signal, news, headlines, and media speculation about United Therapeutics that are available to investors today. That information is available publicly through United media outlets and privately through word of mouth or via United internal channels. However, regardless of the origin, that massive amount of United data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of United Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of United Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to United Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive United Therapeutics alpha.